About the PSI Myanmar Project

Recently, I wrote about Good Ventures' decision to co-fund a project with the Bill & Melinda Gates Foundation and the UK Department for International Development. The project, which is being carried out by Population Services International (PSI), aims to contain and eliminate growing drug resistance to the highly effective antimalarial medication artemisinin in Myanmar.

My last post covered our reasons for pursuing co-funding opportunities and how we selected the PSI Myanmar project. Today, GiveWell, which is assisting Good Ventures in researching co-funding opportunities, published a report summarizing what we've learned to date about the project. It's available at www.givewell.org/PSI-Myanmar-Artemisinin-Resistance-Containment.